Multicenter evaluation of patients with cutaneous malignant melanoma in Turkey: MELAS study.
Malignant melanoma is a cancer that demonstrates rapid progression and atypical clinically features with a poor prognosis. This study was performed to determine the clinical characteristics and treatment outcomes of patients with malignant melanoma in Turkey. The medical records of 98 patients between 2007- 2012 at our centers were retrieved from the patient registry. Overall survival (OS) was calculated using the Kaplan-Meier method. In our study, with the median follow-up of all patients with cutaneous MM of 46.3 months, the median OS rate of all cases was 43.6 months and 5-year OS was 48.6%. However, five-year OS rates of patients with localized disease (stage I-II) and node involvement (stage III) were 60.3% and 39.6%, respectively. The median OS of stage IV patients was 8.7 months and 1-year OS rate was 26.2%. We showed that advanced stage, male gender, and advanced age in all patients with MM were significant prognostic factors of OS. Compared with the results of current studies from Western countries, we found similar findings concerning demographical features, histological variables and survival analyses for our patients with cutaneous MM in Turkey.